IHH Healthcare reported a net profit of RM573 million for the second quarter of fiscal year 2026 ended June 30, up 29.3% from RM443 million in the same quarter last year [1, 2, 3]. Earnings per share rose to 6.48 sen from 5.02 sen a year earlier [1, 2, 3].
Revenue for Q2 increased about 12% to approximately RM7.05 billion, driven by growth in patient volume, improved case mix, and price adjustments across its markets [1, 2, 3]. For the first half of 2026, IHH's net profit rose 15% year-on-year to RM1.1 billion, while revenue grew 8% to RM13.6 billion [1, 3].
The company's improved results reflected stronger contributions from Turkey and Europe as well as Malaysia and Greater China. These gains offset declines in Singapore and India, the company said [1, 2]. Analysts at Hong Leong, RHB, and UOB Kay Hian upgraded IHH stock to "buy" following the stronger-than-expected Q2 earnings [3].
On August 27, 2026, IHH Healthcare declared an interim dividend of 5.5 sen per share, payable on October 30, 2026 [1, 2]. Despite the positive earnings and dividend news, IHH’s share price on Bursa Malaysia closed 0.97% lower at RM8.15, while it ended flat at SGD 2.65 on the Singapore Exchange [1, 2].
The company acknowledged that the operating environment remains challenged by macroeconomic and geopolitical uncertainties but emphasized its focus on long-term strategy. A statement read, "While the operating environment is influenced by broader macroeconomic and geopolitical uncertainties, the group remains focused on executing its long-term strategy to deliver sustainable growth and value creation" [1].
IHH's market valuation after the August 27 close stood at RM72.01 billion [1]. The next major corporate event is the scheduled payment of the interim dividend on October 30, 2026 [1, 2].
